Skip to main content

Fiscal Wizard · Single-issue tearsheet

SLP / Jun 21, 2026 Run #7552

SLP

Simulations Plus, Inc.

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. It operates through Software and Services segments. The company offers GastroPlus, which predicts absorption, biopharmaceutics, pharmacokinetics, and pharmacodynamics in humans and animals; and DDDPlus and MembranePlus simulation products. It also provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, OBESITYsym, and Thales products. In addition, the company offers Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Further, it provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Additionally, the company offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Research Triangle Park, North Carolina.

Composite verdict

B 73.7 / 100
Bullish setup · Trend Following 19 drivers · 2 gates blocking
  • Parabolic SAR Flip
  • Rate of Change
  • MACD Signal Cross
Consider long call target Δ ~0.60 · ~35 DTE Bullish setup, Grade B → ITM call target

Industry rank 2nd of 47 in Health Information Services

rescore-sweep
Technical synthesisRegime: uptrend
Bull 100%Evidence: High · 22 signals0% Bear
Momentum Bullish 98Mean-reversion Neutral 51

No notable composite patterns — the signals don't cluster into a named setup right now.

Where value comes fromMargin of safety -62%

Earnings power doesn't cover the capital structure (high debt) — the EPV decomposition isn't meaningful for this name.

Fundamentals Mixed

47.3 / 100

Score-bearing fundamentals shown here exclude gate-only risk checks. · 35 metrics shown.

Strongest
Weakest
FCF Margin 76
Margin of Safety 0
EBITDA Margin 75
EPS Growth (YoY) 0
Return on Capital Employed 75
Return on Assets 24

Technicals Bullish

100.0 / 100

Bullish setup leads (Parabolic SAR Flip, Rate of Change, MACD Signal Cross); bears gated by guards. · 43 signals shown.

Strongest
Weakest
Parabolic SAR Flip 93
Rate of Change 93
MACD Signal Cross 89

Risk Gates

2 blocking 5 caution

2 guards active, 20 signals gated.

MA Crossover Blocking

Blocks counter-regime signals only when the MA crossover agrees with the long-term regime.

Regime Filter Blocking

Blocks signals that oppose the long-term moving-average regime.

Cash Ratio Caution

Visual cash-cushion flag — does not mute signals.

Current Ratio Caution

Visual liquidity flag — does not mute signals.

Breakdown

Look under the hood

Empty pane

Pick a category, above, to crack it open.

Every chip in either subscore card drills into the metrics or signals that fed it — including the formula, the threshold band, and what the current reading means for SLP.